Cargando…
CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation
Bladder cancer (BC) and melanoma are amenable to immune checkpoint blockade (ICB) therapy, yet most patients with advanced/metastatic disease do not respond. CD122-targeted interleukin (IL)-2 can improve ICB efficacy, but mechanisms are unclear. We tested αPD-L1 and CD122-directed immunotherapy with...
Autores principales: | Reyes, Ryan M, Zhang, Chenghao, Deng, Yilun, Ji, Niannian, Mukherjee, Neelam, Padron, Alvaro S, Clark, Curtis A, Svatek, Robert S, Curiel, Tyler J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632314/ https://www.ncbi.nlm.nih.gov/pubmed/34858732 http://dx.doi.org/10.1080/2162402X.2021.2006529 |
Ejemplares similares
-
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
por: Reyes, Ryan Michael, et al.
Publicado: (2021) -
$^{120}$Cd and $^{122}$Cd
por: Scheidemann, Ø, et al.
Publicado: (1973) -
Intratumoral CD56(bright) natural killer cells are associated with improved survival in bladder cancer
por: Mukherjee, Neelam, et al.
Publicado: (2018) -
TREM2 promotes natural killer cell development in CD3(−)CD122(+)NK1.1(+) pNK cells
por: Lee, Hwa-Youn, et al.
Publicado: (2021) -
Essential Roles of CD8(+)CD122(+) Regulatory T Cells in the Maintenance of T Cell Homeostasis
por: Rifa'i, Muhaimin, et al.
Publicado: (2004)